Company Profile

Minerva Biotechnologies Corporation
Profile last edited on: 5/6/22      CAGE: 1RJ37      UEI:

Business Identifier: Cancer immunotherapies and drugs to target 80% of solid tumors and to prevent cancer metastasis
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

40 Bear Hill Road
Waltham, MA 02451
   (781) 487-0200
Location: Single
Congr. District: 05
County: Middlesex

Public Profile

Originally organized around the Founder's work pre-dating founding of Minerva Biotechnologies, involved in using nanoparticles in fields such as drug discovery, proteomics, opto-electronics and nanoscale biosensors, in 2001 management of the firm shifted strategy to use its nanoparticle technology in-house to develop and identify potential drug candidates. Minerva had been first to discover that cancer cells hijack an otherwise normal stem cell growth mechanism, involving a growth factor receptor called MUC1* (pronounced muk 1 star). By studying human stem cells in parallel with human cancer cells, Minerva scientists determined how cancer cells override the normal ‘shut off’ switch that stops stem cells from self-replicating indefinitely. This critical insight is enabling Minerva to develop a new class of anti-cancer and anti-metastasis drugs. The Company is developing anti-cancer drugs that target a cancer-specific growth factor receptor and a testis specific cancer antigen that promotes metastasis. The drugs being developing are antibody-based drugs (biologicals) that would address 80% of all solid tumor cancers and even higher percentages of metastatic cancers. Minerva’s proprietary cancer-targeting antibodies have also been integrated into chimeric antigen receptors (CARs) for T cell immunotherapy. Beginning in 2015, Minerva marketed its naïve state human iPS (induced pluripotent stem) cells and its naïve-inducing stem cell growth factor and reagents. Minerva is the first company to generate human naïve state pluripotent stem cells using a single, naturally occurring human stem cell growth factor. These earlier stem cells have a clean slate, and are more easily directed to develop into functional mature cells, which could be used for tra

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 1 NIH $209,520
Project Title: Novel Therapeutic for Hematopoietic Stem Cell Regeneration in Bone Marrow Post My
2008 1 NIH $181,320
Project Title: Novel Agents For The Proliferation Of Stem Cells
2006 2 NIH $398,040
Project Title: Nanoparticle System for High Throughput Proteomics
2002 2 NIH $873,852
Project Title: Rapid Electronic Detection of Cell Surface Proteins
2002 2 NIH $994,439
Project Title: Electronic Sensing of Neurodegenerative Disease Fibrils

Key People / Management

  Cynthia C Bamdad -- Founder President and CEO

  Ron Axelrod -- Chief Operating Officer

  Mark Carter -- Scientist

  Molly Jenkins -- Scientist

  Sanjeev Mahanta -- Group Leader, Biology

  Normand F Smith -- Secretary & Director

  Andrew Stewart -- Senior Project Manager

  D Thompson